{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-075757","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2026-07-07T12:05:25+00:00","discovered_at":"2026-07-07T12:10:00.648686+00:00","generated_at":"2026-07-07T12:10:14.881069+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Turn Therapeutics Announces Final Stage 2 Design and Expansion of GX-03 Phase 2 Trial","bullets":["Interim analysis of GX-03 Phase 2 trial in atopic dermatitis showed Week 4 vIGA-AD Success 71.4% vs 33.3% vehicle in EASI 1.1-7.0 subgroup.","Final Stage 2 design will enroll 120-135 patients across full EASI spectrum (≥1.1) using Hochberg multiple testing procedure for four endpoints.","GX-03 demonstrated favorable safety with no treatment-related serious adverse events or discontinuations reported.","Company expects to complete enrollment in Q4 2026 and is capitalized through Q3 2027.","Turn Therapeutics hosted an investor webcast on July 7, 2026 at 4:30 PM ET to discuss the results."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-075757","json":"https://secwatch.observer/filing/0001213900-26-075757.json","markdown":"https://secwatch.observer/filing/0001213900-26-075757.md","text":"https://secwatch.observer/filing/0001213900-26-075757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026075757/0001213900-26-075757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026075757/ea0297061-8k_turn.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T12:10:14.881069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}